Bone morphogenic protein-2 (BMP-2) loaded hybrid coating on porous hydroxyapatite scaffolds for bone tissue engineering.

In this study, a silica xerogel-chitosan hybrid is utilized as a coating material to incorporate bone morphogenic protein-2 (BMP-2) on a porous hydroxyapatite (HA) scaffold for bone tissue engineering. BMP-2 is known as a therapeutic agent for improving bone regeneration and repair. Silica xerogel-chitosan hybrids have been used for the delivery of a growth factor as well as osteoconductive coatings. The biological properties of the hybrid coating incorporated with BMP-2 were evaluated in terms of the BMP-2 release behavior, osteoblastic cellular responses and in vivo performance. BMP-2 was continuously released from the hybrid coating layer on the porous HA scaffold for up to 6 weeks. The hybrid coating containing BMP-2 showed significantly enhanced osteoblastic cell responses in comparison with the hybrid coating and HA substrate. Consequently, new bone formation was significantly increased within the hybrid coating containing BMP-2. These results reveal that the hybrid coating containing BMP-2 has the potential to be used as a bone implant, whose osteogenic properties are promoted by the release of BMP-2 in a controlled manner for a prolonged period of time.

Silica-chitosan hybrid coating on Ti for controlled release of growth factors.

A hybrid material composed of a silica xerogel and chitosan was coated on Ti for the delivery of growth-factors. Fibroblast growth factor (FGF) and green fluorescence protein were incorporated into the coatings for hard tissue engineering. Silica was chosen as a coating material because of its high surface area as well as its good bioactivity. Chitosan provides mechanical stability and contributes to the control of the release rate of the growth factors. When the chitosan composition was 30% or more, the hybrid coating was stable physically and mechanically. The release of the growth-factors, observed in phosphate buffer solution at 37°C, was strongly dependent on the coating material. The hybrid coating containing FGF showed significantly improved osteoblast cell responses compared to the pure xerogel coating with FGF or the hybrid coating without FGF. These results indicate that the hybrid coating is potentially very useful in enhancing the bioactivity of metallic implants by delivering growth-factors in a controlled manner.

Silica xerogel-chitosan nano-hybrids for use as drug eluting bone replacement.

Silica xerogel-chitosan hybrids containing vancomycin were fabricated by the sol-gel process at room temperature and their potential as a drug eluting bone replacement was evaluated in terms of their mechanical properties and drug release behaviors. Regardless of the content of chitosan, all of the prepared hybrids had a uniform mesoporous structure, which would allow the effectual loading of vancomycin. As the content of chitosan was increased, the strength, strain to failure, and work of fracture of the hybrids were significantly enhanced, while the elastic modulus was decreased. These changes in the mechanical properties were mainly attributed to the mitigation of the brittleness of the silica xerogel through its hybridization with the flexible chitosan phase. In addition, the initial burst-effect was remarkably reduced by increasing the content of chitosan. The hybrids with more than 30% chitosan could release the vancomycin for an extended period of time in a controlled manner.

Collagen-silica xerogel nanohybrid membrane for guided bone regeneration.

A collagen-silica xerogel hybrid membrane was fabricated by a sol-gel process for guided bone regeneration (GBR). The silica xerogel synthesized by the sol-gel method was distributed uniformly within the collagen matrix in the form of nanoparticles. The hybridization of the silica xerogel with collagen improved the biological properties of the membrane significantly. Preosteoblast cells were observed to adhere well and grow much more actively on the hybrid membrane than on the pure collagen membrane. In particular, the hybrid membrane containing 30% of the silica xerogel showed the highest level of osteoblast differentiation. Moreover, the GBR ability, as assessed by the in vivo animal test, was superior to that of the pure collagen membrane. These findings suggest that the collagen-silica xerogel hybrid can be used as a GBR membrane.

A bioactive coating of a silica xerogel/chitosan hybrid on titanium by a room temperature sol-gel process.

A bioactive coating consisting of a silica xerogel/chitosan hybrid was applied to Ti at room temperature as a novel surface treatment for metallic implants. A crack-free thin layer (<2 microm) was coated on Ti with a chitosan content of >30 vol.% through a sol-gel process. The coating layer became more hydrophilic with increasing silica xerogel content, as assessed by contact angle measurement. The hybrid coatings afforded excellent bone bioactivity by inducing the rapid precipitation of apatite on their surface when immersed in a simulated body fluid (SBF). Osteoblastic cells cultured on the hybrid coatings were more viable than those on a pure chitosan coating. Furthermore, the alkaline phosphate activity of the cells was significantly higher on the hybrid coatings than on a pure chitosan coating, with the highest level being achieved on the hybrid coating containing 30% chitosan. These results indicate that silica xerogel/chitosan hybrids are potentially useful as room temperature bioactive coating materials on titanium-based medical implants.

Functionally gradient chitosan/hydroxyapatite composite scaffolds for controlled drug release.

This study explored the potential of chitosan/hydroxyapatite (HA) composites to act as a controlled drug delivery system by developing functional scaffolds with a gradient of structure and drug concentration. Firstly, a porous composite scaffold was prepared and tetracycline hydrochloride (TCH) was impregnated in the scaffold as a model drug. The pore size of the scaffold was negatively dependent on the HA content and ranged about 40-250 microm. Subsequently, a porous chitosan/HA composite layer without drug was coated on the scaffold to create a gradient drug concentration in the specimen. The in vitro drug-release test demonstrated that the porous layer without drug on the outer surface of the scaffold significantly reduced the initial burst of drug release and extended the release period. Finally, a successive and dense chitosan/HA composite layer endowed the scaffold with a sustained, drug-release pattern without any initial drug burst. These findings confirmed the high effectiveness of the hybrid scaffolds in regulating the release of drugs, and hence their capability to serve as a temporary drug carrier in tissue regeneration. These functional scaffolds also have potential application to the delivery of some bioactive molecules such as growth factors.